Q-omics provides the consensus-scored ZNF528 profile across patient tissues and cancer cell-line models. ZNF528 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ZNF528 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ZNF528 RNA expression shows 20,598 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, COAD, and THYM as cancer lineages where ZNF528 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF528 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF528 survival associations across molecular data types. ZNF528 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF528 RNA expression–survival associations across cancer types. High ZNF528 expression shows unfavorable associations in LGG, MESO, STAD and READ, but favorable associations in OV and BLCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ZNF528 RNA expression.
This table summarizes ZNF528 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF528. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF528 shows lower tumor expression in COAD, KICH, ESCA and READ and higher tumor expression in KIRC and CHOL. The COAD box plot shows higher ZNF528 RNA expression in normal versus tumor tissue (log2 FC = −0.838, t-test p < 0.001).
This table shows molecular features associated with ZNF528 in patient tissues and cancer cell lines. In patient samples, ZNF528 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF528 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
